A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
Read more: More Efficient DNA Technology for Targeted Disease Detection and Treatment
The Latest on: DNA technology
[google_news title=”” keyword=”DNA technology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: DNA technology
- Integrated DNA Technologies, Inc.: Integrated DNA Technologies and Molecular Health Ink Commercial Partnershipon May 15, 2024 at 5:56 am
Strategic partnership enables companies to combine technology offerings and streamline NGS workflows Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health ...
- Integrated DNA Technologies and Molecular Health Ink Commercial Partnershipon May 15, 2024 at 5:45 am
IDT and Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their NGS capabilities.
- Collaboration aims to unravel role of DNA damage in ALSon May 15, 2024 at 5:01 am
Broken String Biosciences and Francis Crick Institute scientists are teaming up to better understand how DNA damage contributes to ALS.
- DNA Analysis Detects Hidden Ingredients in Commercially Available Supplementson May 15, 2024 at 1:38 am
A recent study reveal that some supplement companies may mislead customers with unproven health claims and undeclared ingredients.
- DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyston May 14, 2024 at 11:58 am
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP ...
- State forensic lab uses cutting-edge DNA technology to solve crimeson May 14, 2024 at 9:38 am
and then make enough copies of that that we can detect or make a DNA profile,” said Jenkins. Making copies — and how small the sample can be —are advancements in technology in recent years, making it ...
- Sonoma sheriff seeks more answers from public after DNA helped ID 1967 homicide victimon May 12, 2024 at 11:00 am
DNA technology has provided inroads into a cold case out of Sonoma County stemming from the 1960s, according to the Sheriff’s Office. The decomposed remains of a woman were found in February 1967 down ...
- From DNA to fingerprints: Pittsburgh detectives say they've tripled success in identifying suspectson May 10, 2024 at 2:22 pm
Police have always relied on science to help them solve crimes and the Pittsburgh Bureau of Police just got some new forensic weapons.
- Maine eyes new DNA technology that could help crack unsolved caseson May 10, 2024 at 9:48 am
Legislators allocated $100,000 to LD 838 to contract with a forensic genetic genealogy company to perform advanced DNA testing on unidentified bodies.
- After nearly 40 years, forensic DNA used to identify victim found on Crescent Beachon May 8, 2024 at 4:48 pm
The St. Johns County Sheriff’s Office announced it has identified the remains of a body found on Crescent Beach nearly 40 years ago.
via Bing News